$375 Million is the total value of Octagon Capital Advisors LP's 20 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $116,806,000 | -1.8% | 2,583,059 | +10.4% | 31.17% | +21.3% |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $67,657,000 | -13.9% | 2,669,974 | +7.2% | 18.06% | +6.3% |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $44,629,000 | +101.1% | 2,551,703 | +88.1% | 11.91% | +148.3% |
| HZNP | Buy | HORIZON THERAPEUTICS PUB L | $26,321,000 | +150.2% | 330,000 | +230.0% | 7.02% | +208.7% |
| GOSS | Buy | GOSSAMER BIO INC | $23,085,000 | +3.8% | 2,758,069 | +7.6% | 6.16% | +28.1% |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $20,527,000 | -20.8% | 761,398 | 0.0% | 5.48% | -2.3% | |
| XBI | Buy | SPDR SER TRs&p biotech | $18,077,000 | +260.5% | 243,400 | +336.2% | 4.82% | +345.0% |
| STOK | Sell | STOKE THERAPEUTICS INC | $10,085,000 | -41.1% | 763,456 | -6.1% | 2.69% | -27.3% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $8,478,000 | -63.2% | 933,743 | -58.8% | 2.26% | -54.5% |
| VERA | VERA THERAPEUTICS INCcl a | $7,826,000 | -42.1% | 575,000 | 0.0% | 2.09% | -28.5% | |
| ARVN | ARVINAS INC | $7,513,000 | -37.5% | 178,500 | 0.0% | 2.00% | -22.8% | |
| RNA | AVIDITY BIOSCIENCES INC | $4,673,000 | -21.3% | 321,641 | 0.0% | 1.25% | -2.9% | |
| FDMT | Sell | 4D MOLECULAR THERAPEUTICS IN | $4,417,000 | -81.4% | 632,745 | -59.6% | 1.18% | -77.0% |
| KROS | Sell | KEROS THERAPEUTICS INC | $4,207,000 | -77.3% | 152,249 | -55.2% | 1.12% | -71.9% |
| RXDX | PROMETHEUS BIOSCIENCES INC | $2,258,000 | -25.3% | 80,000 | 0.0% | 0.60% | -7.7% | |
| IMVT | Sell | IMMUNOVANT INC | $2,258,000 | -72.2% | 579,061 | -60.7% | 0.60% | -65.7% |
| IMAB | Sell | I MABsponsored ads | $2,259,000 | -86.7% | 199,876 | -81.0% | 0.60% | -83.6% |
| IPSC | Sell | CENTURY THERAPEUTICS INC | $2,184,000 | -73.6% | 260,000 | -60.5% | 0.58% | -67.5% |
| MREO | New | MEREO BIOPHARMA GROUP PLCads | $1,120,000 | – | 1,000,000 | +100.0% | 0.30% | – |
| AMAM | Sell | AMBRX BIOPHARMA INCsponsored ads | $325,000 | -47.2% | 122,800 | -17.8% | 0.09% | -34.6% |
| CNTB | Exit | CONNECT BIOPHARMA HLDGS LTDads | $0 | – | -279,921 | -100.0% | -0.18% | – |
| Exit | OMEGA THERAPEUTICS INC | $0 | – | -176,470 | -100.0% | -0.24% | – | |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -525,284 | -100.0% | -1.10% | – |
| SURF | Exit | SURFACE ONCOLOGY INC | $0 | – | -2,300,000 | -100.0% | -1.46% | – |
| ITOS | Exit | ITEOS THERAPEUTICS INC | $0 | – | -450,776 | -100.0% | -3.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.